Anti-PD-1? Well, no, says Medivation as a partial hold forces a halt to ‘pivotal’ cancer study

John Carroll When Medivation bought out the rights to CureTech's pidilizumab, it trumpeted its entry into checkpoint inhibition with a drug that aimed right at PD-1, unleashing ...

U.K.’s NICE says yes to Opdivo for advanced skin cancer

Eric Palmer Last month the U.K. drug cost watchdog nixed Bristol-Myers Squibb's immunotherapy Opdivo for use against lung cancer, saying in draft guidance that it just cost too ...

Pfizer looks to Russian partnership to produce some of its meds there, report says

Eric Palmer Russia's economy has gotten ugly in the past few years, but that has not dampened the enthusiasm of Big Pharma, which continues to like the look of one of the world's ...

Crippled by 2 deaths, Zafgen says obesity drug cut weight in PhIII

John Carroll With its clinical development program for a new obesity drug in limbo following the unexplained deaths of two patients, Zafgen reported today that the troubled Phase III ...

Don’t split up the dynamic duo of GSK’s vaccines and drugs, vax chief says

Carly Helfand Prominent U.K. investor Neil Woodford has been calling for a four-way breakup of GlaxoSmithKline, a company he says is too "complicated" for its own good. But ...

Cipla says top 50 drugs in development could bring in $30B

John Carroll Indian drugmaker Cipla said it currently has 200 drugs in development and that the top 50 of those drugs have the potential to earn the company more than $ 30 billion. FierceBiotech ...

Depomed isn’t anti-takeover, CEO says. It was just anti-Horizon

Carly Helfand SAN FRANCISCO–Let Depomed be clear: it may not have been too keen on Horizon Pharma's buyout offer from last year, but that doesn't mean it's opposed ...

GSK’s new $32,500 asthma med costs at least 2X too much, U.S. pricing watchdog says

Carly Helfand GlaxoSmithKline has a new drug that's tailored for patients with a specific type of severe asthma. But according to a nonprofit body that evaluates drugs' prices ...

In pharma M&A, 2015 trumps red-hot 2014 so far, report says

Carly Helfand Global activity in the pharma, medical and biotech spheres over the first three quarters of this year has hit its largest-to-date value since at least 2001, according ...

J&J says it has plenty of firepower for M&A, buyback or no buyback

Carly Helfand Johnson & Johnson may be embarking on a $ 10 billion share repurchase program, but that doesn't mean it doesn't have room to make deals. FiercePharma News

Zafgen finally breaks its silence, says it’s probing death of a patient

John Carroll More than two days after Zafgen's stock started to get crushed under the heavy weight of speculation surrounding its sudden decision to cancel a roadshow presentation ...

U.K. cost gatekeeper says ‘OK’ to Merck’s Keytruda for advanced skin cancer

Emily Wasserman Merck's Keytruda got a green light from the U.K.'s cost effectiveness gatekeeper to treat patients with advanced skin cancer, chalking up another victory as ...
Page 1 of 812345...Last »
© 2017 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS